Physician profile
D Scott Upton
NPI 1417994898
$1,424.41
in general payments reported to CMS, 2019-2025
28 companies · $552 in 2025
The $552 reported for 2025 was more than what 75% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $97.78 · 2020: $44.61 · 2021: $102 · 2022: $253 · 2023: $183 · 2024: $193 · 2025: $552.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $878 · Education: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $877.52 |
| Education | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $189.40 | 2022-2025 | |
| Actelion Pharmaceuticals US, INC. | $149.14 | 2025 | Uptravi, Opsumit |
| Antares Pharma, INC. | $146.73 | 2021-2022 | |
| Pfizer INC. | $146.11 | 2019-2025 | |
| Lilly USA, LLC | $117.97 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $71.23 | 2022-2023 | Ubrelvy |
| Astellas Pharma US INC | $62.54 | 2024-2025 | Veozah |
| Medtronic, INC. | $59.90 | 2025 | Symplicity G3 |
| Currax Pharmaceuticals LLC | $50.00 | 2023 | Nexletol |
| Abbott Laboratories | $44.88 | 2024 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.76 | 2022-2023 | Tradjenta, Jardiance |
| E.R. Squibb & Sons, L.L.C. | $32.10 | 2019-2021 | |
| Dexcom, INC. | $28.60 | 2021 | |
| Alnylam Pharmaceuticals INC. | $28.25 | 2025 | Amvuttra |
| Sanofi-Aventis U.S. LLC | $28.10 | 2024 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alk-Abello, INC | $27.32 | 2025 | Neffy |
| Glaxosmithkline, LLC. | $22.31 | 2019 | |
| Novo Nordisk INC | $20.92 | 2023 | Saxenda, Wegovy |
| Amgen INC. | $20.13 | 2024 | Repatha |
| Biohaven Pharmaceutical Holding Company LTD. | $19.31 | 2022 | |
| Kaleo, INC. | $19.16 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $18.72 | 2022 | |
| Janssen Pharmaceuticals, INC | $14.61 | 2019 | |
| Seqirus USA INC | $13.99 | 2021 | |
| Cranial Technologies, INC | $13.85 | 2022 | |
| Allergan, INC. | $13.25 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $12.75 | 2019 | |
| Irhythm Technologies, INC. | $12.38 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw D Scott Upton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.